Welcome to our dedicated page for STAAR news (Ticker: STAAR), a resource for investors and traders seeking the latest updates and insights on STAAR stock.
The STAAR Surgical Company (STAAR) news page on Stock Titan aggregates coverage related to the company’s role in phakic intraocular lenses and its proposed acquisition by Alcon. In a recent Business Wire announcement, STAAR is described as a global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, and this same communication outlines an amended merger agreement between STAAR and Alcon.
News about STAAR currently centers on the terms and implications of this amended merger agreement. The announcement details that Alcon and STAAR have agreed on revised economic terms, that the Boards of Directors of both companies have approved the amended agreement, and that the STAAR Board has recommended stockholders vote in favor of the transaction. It also explains that a prior go-shop period concluded without a superior proposal and that the transaction remains subject to regulatory approvals and stockholder consent.
On this page, readers can follow developments related to the proposed merger process, including updates about the special stockholder meeting, proxy materials, and any additional communications regarding the transaction. Because the most recent public information emphasizes the merger and STAAR’s EVO ICL technology, news coverage is likely to focus on transaction milestones, regulatory steps, and commentary from the companies about the rationale for combining Alcon’s eye care platform with STAAR’s phakic IOL technology.
Investors and observers who want to monitor how the proposed acquisition evolves, how STAAR communicates with its stockholders, and how Alcon frames the strategic value of STAAR’s technology can use this news feed as a centralized reference for transaction-related announcements and related corporate communications.
Alcon (SIX/NYSE: ALC) announced an amended merger agreement to acquire STAAR Surgical (NASDAQ: STAA) for $30.75 per share in cash, increasing the offer by roughly $150 million of equity value. The transaction represents an approximate $1.6 billion total equity value, a 74% premium to STAAR’s 90-day VWAP and a 66% premium to STAAR’s August 4, 2025 closing price.
Alcon said it will finance the deal with short- and long-term credit facilities, expects the merger to be accretive to earnings in year two, and anticipates closing in early 2026, subject to regulatory and STAAR stockholder approvals. STAAR stockholders are urged to vote ahead of a December 19, 2025 meeting.